NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling ...

Physicians also expect greater use of Johnson & Johnson’s Varipulse system over the next two years despite the company’s ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

Analysts expect a profit per share of $2.02, which is a decline of 11.8% from the prior year period. The consensus revenue ...

Johnson & Johnson MedTech has temporarily halted the US rollout of its Varipulse heart device as it investigates four reported stroke events. The suspension, which began on 5 January, affects the ...

Johnson & Johnson halted U.S. Varipulse cases after four reported neurovascular events during external evaluation trials. Over 130 U.S. cases and 3,000 global commercial cases have been performed ...

Investing.com -- Shares of Johnson & Johnson (NYSE:JNJ) fell 3% amid concerns regarding its cardiac ablation device, Varipulse. The movement comes after Wells Fargo (NYSE:WFC) released a research ...